Success Metrics

Clinical Success Rate
33.3%

Based on 1 completed trials

Completion Rate
33%(1/3)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
2(67%)

Phase Distribution

Ph not_applicable
1
33%
Ph phase_3
2
67%

Phase Distribution

0

Early Stage

0

Mid Stage

2

Late Stage

Phase Distribution3 total trials
Phase 3Large-scale testing
2(66.7%)
N/ANon-phased studies
1(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

33.3%

1 of 3 finished

Non-Completion Rate

66.7%

2 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Completed(1)
Terminated(2)

Detailed Status

Terminated2
Completed1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
33.3%
Most Advanced
Phase 3

Trials by Phase

Phase 32 (66.7%)
N/A1 (33.3%)

Trials by Status

terminated267%
completed133%

Recent Activity

0 active trials
Showing 3 of 3
completedphase_3

Adaptive Use of Nicotine Substitution to Maintain Smoking Reduction/Abstinence in Nicotine Responders

NCT06554873
terminatedphase_3

Evaluate Harm Reduction Products as a Second Line Intervention for Adult Smokers Who Do Not Quit With NRT

NCT06088862
terminatednot_applicable

Cytisine Compared to Combination NRT in Relapsed Smokers

NCT04286295

Clinical Trials (3)

Showing 3 of 3 trials
NCT06554873Phase 3

Adaptive Use of Nicotine Substitution to Maintain Smoking Reduction/Abstinence in Nicotine Responders

Completed
NCT06088862Phase 3

Evaluate Harm Reduction Products as a Second Line Intervention for Adult Smokers Who Do Not Quit With NRT

Terminated
NCT04286295Not Applicable

Cytisine Compared to Combination NRT in Relapsed Smokers

Terminated

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3